The Efficacy of Bleomycin Lipiodol in Reduction Size of Large Hepatic Hemangioma
DOI:
https://doi.org/10.59675/U315Keywords:
Hepatic hemangioma, Bleomycin, Lipiodol, Transarterial embolization, Minimally invasive therapy, Liver tumor.Abstract
Background: Hepatic hemangiomas are the most common benign tumors of the liver. Most hepatic hemangiomas are asymptomatic but can be symptomatic or sufficiently large for therapeutic intervention (usually considered if > 4–5 cm). Transarterial embolization (TAE) for hepatic hemangioma provides a minimally invasive option using bleomycin and lipiodol and is becoming more commonly used, but prospective studies evaluating its efficacy have been limited.
Methods: A cohort prospective study was performed to investigate the effect of transcatheter arterial embolization on large hepatic hemangiomas (>5 cm) in 16 adult patients (15 females, 1 male; mean age 38 ± 7.7 years), who presented with symptomatic hepatic hemangiomas for 6 months or longer. All patients underwent TAE with a combination of 15 IU bleomycin and 10 mL lipiodol. Hemangioma size and volume were measured by triphasic CT imaging pre- and post-TAE at a mean follow-up of 9 months. Duration of symptom resolution and complications following TAE were also recorded.
Results: Following the embolization, mean lesion diameters were significantly decreased by 25.75% (craniocaudal), 20.06% (transverse), and 24.1% (anteroposterior) (p < 0.001). The mean volumetric reduction was 65.2%. Every patient experienced clinical improvement of their pain, discomfort, and abdominal fullness. There were no major complications, transient post-embolization syndrome was self-limited.
Conclusion: TAE with Bleomycin/Lipiodol seems to be a safe and effective minimally invasive approach for large symptomatic hepatic hemangiomas. The reduction in the size of the lesion, significant symptom relief, and durability, suggest its place in the management strategy as an alternative to surgery. Larger multicenter studies, with extended follow-up studies, would add further evidence to the results found in this review.
Downloads
References
Caseiro-Alves F, Brito J, Araujo AE, Belo-Soares P, Rodrigues H, Cipriano A, et al. Liver haemangioma: common and uncommon findings and how to improve the differential diagnosis. European radiology. 2007;17:1544-54. DOI: https://doi.org/10.1007/s00330-006-0503-z
Kacała A, Dorochowicz M, Matus I, Puła M, Korbecki A, Sobański M, et al. Hepatic Hemangioma: Review of Imaging and Therapeutic Strategies. Medicina (Kaunas). 2024;60(3). DOI: https://doi.org/10.3390/medicina60030449
Aziz H, Brown ZJ, Baghdadi A, Kamel IR, Pawlik TM. A comprehensive review of hepatic hemangioma management. Journal of Gastrointestinal Surgery. 2022;26(9):1998-2007. DOI: https://doi.org/10.1007/s11605-022-05382-1
Ayturk UM, Couto JA, Hann S, Mulliken JB, Williams KL, Huang AY, et al. Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma. Am J Hum Genet. 2016;98(4):789-95. DOI: https://doi.org/10.1016/j.ajhg.2016.03.009
Reggiani Bonetti L, Boselli F, Lupi M, Bettelli S, Schirosi L, Bigiani N, et al. Expression of estrogen receptor in hemangioma of the uterine cervix: reports of three cases and review of the literature. Arch Gynecol Obstet. 2009;280(3):469-72. DOI: https://doi.org/10.1007/s00404-009-0928-0
Mogahed MM, Zytoon AA, Essa B, Abdellatif W, Ghanem N, ElWakeel B. Natural history of hepatic hemangiomas as a guide for surgical indication. Egyptian Liver Journal. 2020;10:1-7. DOI: https://doi.org/10.1186/s43066-020-00065-5
Sandulescu LD, Urhut CM, Sandulescu SM, Ciurea AM, Cazacu SM, Iordache S. One stop shop approach for the diagnosis of liver hemangioma. World J Hepatol. 2021;13(12):1892-908. DOI: https://doi.org/10.4254/wjh.v13.i12.1892
Zhang Z-H, Jiang C, Li J-X. Reconsideration of the clinical management of hepatic hemangioma. World Journal of Gastrointestinal Surgery. 2024;16(11):3623. DOI: https://doi.org/10.4240/wjgs.v16.i11.3623
Mannino M, Toro A, Palumbo V, Di Carlo I. Hepatic hemangiomas of the liver: when operate and with which vascular exclusion. Annals of Laparoscopic and Endoscopic Surgery. 2018;3(1). DOI: https://doi.org/10.21037/ales.2018.01.06
Wu S, Gao R, Yin T, Zhu R, Guo S, Xin Z, et al. Complications of Radiofrequency Ablation for Hepatic Hemangioma: A Multicenter Retrospective Analysis on 291 Cases. Front Oncol. 2021;11:706619. DOI: https://doi.org/10.3389/fonc.2021.706619
Yuan B, Zhang J-L, Duan F, Wang M-Q. Medium and long-term outcome of superselective transcatheter arterial embolization with lipiodol–bleomycin emulsion for giant hepatic hemangiomas: results in 241 patients. Journal of Clinical Medicine. 2022;11(16):4762. DOI: https://doi.org/10.3390/jcm11164762
Zhang W, Chen G, Ren JG, Zhao YF. Bleomycin induces endothelial mesenchymal transition through activation of m TOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations. British Journal of Pharmacology. 2013;170(6):1210-20. DOI: https://doi.org/10.1111/bph.12355
Ghaemi O, Mehrabi Nejad MM, Rouhezamin MR, Ayoobi Yazdi N, Pourghorban R, Rokni Yazdi H. A technical review of percutaneous sclerotherapy with bleomycin for giant hepatic venous malformation. CVIR Endovasc. 2023;6(1):46. DOI: https://doi.org/10.1186/s42155-023-00394-7
Kacała A, Dorochowicz M, Korbecki A, Sobański M, Puła M, Patrzałek D, et al. Transarterial Bleomycin-Lipiodol Chemoembolization for the Treatment of Giant Hepatic Hemangiomas: An Assessment of Effectiveness. Cancers (Basel). 2024;16(2). DOI: https://doi.org/10.3390/cancers16020380
Dong Z, Fang K, Sui C, Guo J, Dai B, Geng L, et al. The surgical outcomes and risk factors of giant hepatic haemangiomas: a single centre experience. BMC surgery. 2022;22(1):278. DOI: https://doi.org/10.1186/s12893-022-01721-w
Torkian P, Li J, Kaufman JA, Jahangiri Y. Effectiveness of transarterial embolization in treatment of symptomatic hepatic hemangiomas: systematic review and meta-analysis. Cardiovascular and interventional radiology. 2021;44:80-91. DOI: https://doi.org/10.1007/s00270-020-02611-5
Kutlu R, Dag N, Saparbekov E, Yagin FH. Non-Target Hemangioma Size Reduction After Bleomycin-Lipiodol Embolization of Primary Hepatic Hemangioma. Journal of Vascular and Interventional Radiology. 2025. DOI: https://doi.org/10.1016/j.jvir.2025.01.042
Furumaya A, Van Rosmalen B, Takkenberg R, Van Delden O, Dejong C, Verheij J, et al. Transarterial (chemo-) embolization and lipiodolization for hepatic haemangioma. HPB. 2020;22:S225-S6. DOI: https://doi.org/10.1016/j.hpb.2020.04.072
Akhlaghpoor S, Torkian P, Golzarian J. Transarterial bleomycin–lipiodol embolization (B/LE) for symptomatic giant hepatic hemangioma. CardioVascular and Interventional Radiology. 2018;41:1674-82. DOI: https://doi.org/10.1007/s00270-018-2010-4
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Academic International Journal of Medical Update
This work is licensed under a Creative Commons Attribution 4.0 International License.
